CA3146050A1 - Compositions de dosage et procedes d'utilisation de composes psychedeliques - Google Patents

Compositions de dosage et procedes d'utilisation de composes psychedeliques Download PDF

Info

Publication number
CA3146050A1
CA3146050A1 CA3146050A CA3146050A CA3146050A1 CA 3146050 A1 CA3146050 A1 CA 3146050A1 CA 3146050 A CA3146050 A CA 3146050A CA 3146050 A CA3146050 A CA 3146050A CA 3146050 A1 CA3146050 A1 CA 3146050A1
Authority
CA
Canada
Prior art keywords
formulation
psychedelic
dmt
combinations
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3146050A
Other languages
English (en)
Inventor
Craig Michael ARNOLD
Parag BHATT
Scott SLAY
Michael S. Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sw Holdings Inc
Original Assignee
Sw Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sw Holdings Inc filed Critical Sw Holdings Inc
Publication of CA3146050A1 publication Critical patent/CA3146050A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles compositions de dosage et des procédés d'utilisation comprenant au moins un composé psychedélique dérivé d'organismes vivants tels que des plantes et des champignons, des formes dérivées synthétiquement ou un analogue synthétique. La composition est destinée à être utilisée dans des systèmes d'administration à dosage, notamment un aérosol nasal, un aérosol-doseur pressurisé, etc.
CA3146050A 2019-07-04 2020-07-03 Compositions de dosage et procedes d'utilisation de composes psychedeliques Pending CA3146050A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870722P 2019-07-04 2019-07-04
US62/870,722 2019-07-04
PCT/US2020/040826 WO2021003467A1 (fr) 2019-07-04 2020-07-03 Compositions de dosage et procédés d'utilisation de composés psychédéliques

Publications (1)

Publication Number Publication Date
CA3146050A1 true CA3146050A1 (fr) 2021-01-07

Family

ID=74100817

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3146050A Pending CA3146050A1 (fr) 2019-07-04 2020-07-03 Compositions de dosage et procedes d'utilisation de composes psychedeliques

Country Status (3)

Country Link
US (1) US20220304980A1 (fr)
CA (1) CA3146050A1 (fr)
WO (1) WO2021003467A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069170A1 (en) * 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
GB202003059D0 (en) * 2020-03-03 2020-04-15 Beckley Found Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
CA3175211A1 (fr) * 2020-04-13 2021-10-21 Matthias Emanuel LIECHTI Identification de dose de lsd
CA3182156A1 (fr) 2020-05-08 2021-11-11 Psilera Inc. Nouvelles compositions de matiere et compositions pharmaceutiques
KR20230012501A (ko) 2020-05-19 2023-01-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
EP3941904A1 (fr) 2020-06-12 2022-01-26 Beckley Psytech Limited Composition pharmaceutique comprenant de la 5-méthoxy-n, n-diméthyltryptamine
IL299449A (en) 2020-06-17 2023-02-01 Psilo Scientific Ltd Standard psychoactive alkaloid extract composition
US20240317704A1 (en) 2020-08-18 2024-09-26 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
CA3113240C (fr) * 2020-12-28 2023-09-05 Psilo Scientific Ltd. Composition d'alcaloide psychoactif transmucosal et preparation connexe
US20220265582A1 (en) * 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
MX2023011602A (es) * 2021-03-31 2024-01-05 Lyfe Chng Llc Sistema transdermico, formulacion y metodo para la administracion terapeutica de un agente psicodelico.
US20220331292A1 (en) * 2021-04-16 2022-10-20 Callitas Health Inc. Compositions and methods for delivery of psilocin and prodrugs thereof
US11602521B2 (en) 2021-04-26 2023-03-14 ATAI Life Sciences AG N,N-dimethyltryptamine compositions and methods
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
IL308068A (en) * 2021-05-03 2023-12-01 Mind Medicine Inc A method for dose titration of psychedelics
US11877986B1 (en) * 2021-05-12 2024-01-23 Trucelium Inc Method of precision dosing
JP2024522065A (ja) * 2021-05-17 2024-06-11 サイビン アイアールエル リミテッド シロシビンの製剤
WO2022261383A1 (fr) 2021-06-09 2022-12-15 ATAI Life Sciences AG Nouveaux promédicaments et conjugués de diméthyltryptamine
US20230059204A1 (en) * 2021-08-03 2023-02-23 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
US20240366655A1 (en) * 2021-09-08 2024-11-07 Cybin Irl Limited Combination drug therapies
EP4159202A1 (fr) * 2021-09-29 2023-04-05 Biomind Labs Inc Formulation pharmaceutique contenant une substance psychédélique obtenue par impression 3d par frittage laser sélectif (sls)
EP4159192A1 (fr) * 2021-09-30 2023-04-05 Biomind Labs Inc Spray nasal à base de diméthyltriptamine pour le traitement personnalisé des troubles neurologiques et psychiatriques
EP4159201A1 (fr) 2021-09-30 2023-04-05 Biomind Labs Inc Nanoparticules encapsulées et nanoparticules de diméthyltriptamines
WO2023115060A1 (fr) * 2021-12-17 2023-06-22 The Regents Of The University Of California Psychoplastogènes pour le traitement de troubles auditifs
US12012381B2 (en) 2021-12-30 2024-06-18 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023168023A1 (fr) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-cristaux ou sels comprenant de la psilocine
WO2023214404A1 (fr) * 2022-05-01 2023-11-09 Short Wave Pharma Inc. Film mucoadhésif comprenant un agent pharmaceutiquement actif et ses utilisations
WO2024028779A1 (fr) * 2022-08-01 2024-02-08 Psyched Wellness Ltd. Formulations et dispositifs de vaporisateur d'amanite tue-mouche
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
WO2024079648A1 (fr) * 2022-10-11 2024-04-18 Sintalica S.R.L. Système d'administration pour la libération contrôlée d'un composé psychédélique, composition pharmaceutique et utilisations associées
TW202423415A (zh) * 2022-10-26 2024-06-16 美商雅特益醫療公司 Ｎ－ｎ－二甲基色胺（ｄｍｔ）及ｄｍｔ類似物組合物、其製造方法及使用方法
WO2024097868A1 (fr) * 2022-11-02 2024-05-10 Caamtech, Inc. Relations structure-activité pour psilocybine, baéocystine, aerugincine et analogues associés pour produire des effets pharmacologiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111880A2 (fr) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Administration intra-nasale de ketamine pour traiter la depression
CA2828884C (fr) * 2011-03-03 2021-04-27 Impel Neuropharma, Inc. Dispositif d'administration de medicament par voie nasale
CN113616883B (zh) * 2014-06-30 2023-06-06 Syqe医药有限公司 向受试者肺部递送植物材料中的至少一药理活性剂的系统
WO2017184531A1 (fr) * 2016-04-18 2017-10-26 Demerx, Inc. Traitement de troubles liés au mouvement au moyen de la noribogaïne
NL2018190B1 (en) * 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid

Also Published As

Publication number Publication date
US20220304980A1 (en) 2022-09-29
WO2021003467A1 (fr) 2021-01-07

Similar Documents

Publication Publication Date Title
CA3146050A1 (fr) Compositions de dosage et procedes d'utilisation de composes psychedeliques
US20240215633A1 (en) Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
US11844763B2 (en) Pharmaceutical composition and method of manufacturing
JP6941224B2 (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
ES2332405T3 (es) Una composicion de nicotina liquida tamponada para administracion pulmonar.
US10045976B2 (en) Nicotine-containing liquid formulations and uses thereof
Wise et al. Sweet taste and menthol increase cough reflex thresholds
US20030084912A1 (en) Composition to reduce or quit smoking addiction
JP7492548B2 (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
US20210077382A1 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
UA126849C2 (uk) Нікотинові композиції для інгаляції та способи їх виготовлення та використання
AU2010360967B2 (en) Nicotine containing formulation
CN103948573A (zh) 一种可镇静助眠和缓解心悸的芳冰鼻用制剂的制备
US20220305223A1 (en) Olfactory Delivery Device, System and Method for the Delivery of a Variety of Pharmaceutical Agents
US20200009126A1 (en) Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction
US10610483B2 (en) Vaporized medicants and methods of use
Alexander Dosage forms and their routes of administration
BR112020015646A2 (pt) Formulações intranasais de epinefrina e métodos para o tratamento de doença
US20220175755A1 (en) Methods of treating tobacco smoking addiction, and treating nicotine and tobacco smoking addiction
WO2006004418A2 (fr) Tabac en capsule